PTC Therapeutics, Inc. (PTCT) Financials
Key financial figures for PTC Therapeutics, Inc. (Q2 2026).
PTC Therapeutics, Inc. reported revenue of $360.5 million for Q2 FY2026, up 101.5% from the same period a year earlier. Net income was $83.5 million, or $0.92 per share. Operating margin came to 41.32%, against -19.54% a year earlier. Free cash flow for the period was $122.0 million. Across the last 5 reported quarters, quarterly revenue has risen from $178.9 million in Q2 FY2025 to $360.5 million in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for PTC Therapeutics, Inc. are on the SentiSense financials page.
- Revenue
- $361M
- Net Income
- $83M
- EPS
- $1.01
- Total Assets
- $3.3B
- Operating Cash Flow
- $129M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $361M | $83M | $0.92 | 41.32% | $122M |
| Q1 FY2026 | $273M | -$3M | -$0.03 | 16.84% | -$60M |
| Q4 FY2025 | $165M | -$135M | -$1.67 | -49.57% | -$72M |
| Q3 FY2025 | $211M | $16M | $0.20 | 1.43% | -$323M |
| Q2 FY2025 | $179M | -$65M | -$0.83 | -19.54% | -$62M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $1.7B | $683M | $7.78 | 49.49% | $411M |
| FY2024 | $807M | -$363M | -$4.73 | -37.5% | -$182M |
| FY2023 | $938M | -$627M | -$8.37 | -46.86% | -$279M |
Frequently asked questions
What was PTC Therapeutics, Inc.'s revenue last quarter?
PTC Therapeutics, Inc. reported revenue of $360.5 million for Q2 FY2026, up 101.5% from the same period a year earlier.
Is PTC Therapeutics, Inc. profitable?
Yes. PTC Therapeutics, Inc. reported net income of $83.5 million for Q2 FY2026, a net margin of 23.16% on revenue.
How has PTC Therapeutics, Inc.'s margin trended?
Operating margin was 41.32% in Q2 FY2026, compared with -19.54% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did PTC Therapeutics, Inc. generate?
PTC Therapeutics, Inc. generated free cash flow of $122.0 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for PTC Therapeutics, Inc. on SentiSense, with up to forty quarters and twenty fiscal years of history.